Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $669.2 million.

  • Axsome Therapeutics' Liabilities and Shareholders Equity rose 1919.86% to $669.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 1027.59%. This contributed to the annual value of $568.5 million for FY2024, which is 335.55% down from last year.
  • As of Q3 2025, Axsome Therapeutics' Liabilities and Shareholders Equity stood at $669.2 million, which was up 1919.86% from $639.8 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Liabilities and Shareholders Equity ranged from a high of $669.2 million in Q3 2025 and a low of $88.6 million during Q1 2022
  • Its 4-year average for Liabilities and Shareholders Equity is $483.9 million, with a median of $561.5 million in 2024.
  • Per our database at Business Quant, Axsome Therapeutics' Liabilities and Shareholders Equity skyrocketed by 33945.11% in 2023 and then tumbled by 1036.76% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Liabilities and Shareholders Equity stood at $331.5 million in 2022, then surged by 77.46% to $588.2 million in 2023, then dropped by 3.36% to $568.5 million in 2024, then rose by 17.72% to $669.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $669.2 million in Q3 2025, compared to $639.8 million in Q2 2025 and $596.7 million in Q1 2025.